19 January 2023

Moderna's vaccine candidate to treat respiratory syncytial virus (RSV) was more than 80% effective at preventing at least two symptoms in a late-stage trial of adults aged 60 or older.

Read more!

___

Gene therapy advancements show promise in treating sickle cell anemia, a condition that affects millions of people worldwide. The below complex research article gives an overview on a branch of their technology.

Read more!

___

A vaccine developed by Dalan Animal Health which protects honeybees against American foulbrood disease has been approved by the US Department of Agriculture. The vaccine is delivered via food given to queen bees so that immunity is passed to developing larvae as they are born / hatch.

Read more!

For the next Carbon Health Healthcare Q&A we are joined again by Dr. Aaron Weinberg to answer your questions about post infectious cough syndrome, or lingering cough.

Watch 'Lingering Cough Q&A'

When a blood vessel (artery or vein) is injured, the damaged cells in the vessel wall recruit platelets and send out chemical signals to form a blood clot. This helps to repair the injured blood vessel. However, if the blood clot is not cleared this can lead to other complications like DVT or PE.

Watch 'How do Blood Clots Form?'

Calling those close to the LA area (or if you know someone nearby)! 

An important national phase II symptom rebound study (C4671042) is underway in collaboration with Pfizer to assess if an additional 5-day course of Paxlovid may provide benefit.

To register interest or for more information, please contact the Carbon4Research team by emailing paxlovidstudy@carbonhealth.com

Do you have a question or something you'd like explained?

I'd love to hear from you and what you would like covered!

Missed a newsletter or just joined?

Approximately 2 weeks after being published, newsletters are archived at drswanda.com/newsletters